Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Alnylam Pharma (ALNY) Stock Price & Analysis
1,038 Followers
ALNY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$141.98 - $218.88
Previous Close$149.4
Volume481.25K
Average Volume (3M)670.97K
Market Cap
$18.90B
Enterprise Value$17.76B
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)-55.7
Beta0.82
Next Earnings
Jul 31, 2024EPS Estimate
-$1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding126,491,778
10 Day Avg. Volume478,743
30 Day Avg. Volume670,970
Standard Deviation0.12
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-84.78
Price to Sales (P/S)10.46
Price to Cash Flow (P/CF)-157.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.79
Enterprise Value/Gross Profit11.39
Enterprise Value/Ebitda-65.96
Forecast
1Y Price Target
$218.29Price Target Upside46.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Financial CollaborationAlnylam's significant milestone payment from Roche for positive Phase 2 results underscores the financial and developmental success of their partnership.
Pipeline DevelopmentAlnylam's diverse pipeline, including a promising Alzheimer's disease study, aligns with its strategic goal of expanding its portfolio by 2025.
Product PerformanceALNY's Amvuttra sees strong demand, exceeding revenue expectations with successful launches in Italy and Spain.
Bears Say
Clinical Trial ConcernsA reduction in enrolled patients may decrease the statistical power of the HELIOS-B trial, which is a concern for investors.
Commercialization ChallengesCommercial positioning of the drug is complicated by payer barriers to combination use, high bars for first-line adoption, and stable disease in many tafamidis patients.
Revenue MissGivlaari revenue was below both analyst and consensus estimates.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $141.97 and its highest was $218.88 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Jul 31, 2024 which is in 74 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on May 02, 2024. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$1.116 by $0.596.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -$1.06.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 126,491,776 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.52 in its last earnings report, beating expectations of -$1.116. Following the earnings report the stock price went up 0.233%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 570M.
---
Alnylam Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$218.29 (46.11% Upside)
$218.29 (46.11% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 41.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.75%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
ALNY Company Deck
---
ALNY Earnings Call
Q1 2024
0:00 / 0:00
---
ALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
ALNY Stock 12 Month Forecast
Average Price Target
$218.29
▲(46.11% Upside)
Technical Analysis
Best Analysts Covering ALNY
1 Year
1 Year Success Rate
20/34 ratings generated profit
1 Year Average Return
+17.96%
reiterated a buy rating 17 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +17.96% per trade.
---